Circio Holding ASA (”Circio” or ”the Company”) announced, on the 21st of May 2026, that it has filed a new patent application with the European Patent Office (EPO), to be expanded subsequently into a global Patent Cooperation Treaty (PCT) application. The invention covers a novel genetic element that improves the efficiency of intracellular circRNA generation by approx. 4-fold and is described by the Company as a critical general design feature for efficient circRNA-based gene expression from vectors. The filing adds to several PCT applications already in place covering multiple aspects of the circVec platform.
In summary, Analyst Group views the EPO filing, if granted, as an incremental reinforcement of the multi-layered circVec IP estate and a further sign of continued platform optimization. Together, these elements would strengthen Circio’s positioning ahead of a catalyst-rich window. The near-term value drivers remain the progressing in vivo CAR-T programme and the Q4-26 cluster of eye and heart disease-model data, the partnered CNS project update, and in vivo CAR-T efficacy readouts, where positive outcomes, combined with a continuously broadened IP base, could support more substantive licensing discussions.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.